University of California, Los Angeles

Toripalimab has received NCCN category 1 recommendation for nasopharyngeal carcinoma based on positive phase 3 data in both first-line and second-line settings, unlike pembrolizumab which showed negative results in the KEYNOTE-122 trial.

Oncologists identify delayed ENT referrals and non-specific respiratory symptoms as primary barriers to timely nasopharyngeal cancer diagnosis.

Children with autism who speak multiple languages demonstrate enhanced cognitive abilities and better control of daily thoughts and actions, according to a recent study published in Autism Research.

UCLA researchers found that men with low-risk prostate cancer who increased omega-3 intake showed a 15% decline in cancer cell proliferation markers, while those on regular diets saw a 24% increase.

Solaxa Inc. has announced plans to conduct a registrational Phase 3 clinical trial for SLX-100, targeting spinocerebellar ataxia type 27B (SCA27B), a rare hereditary neurological disorder with no FDA-approved treatments.

Meta-analysis of six phase III trials reveals patients experiencing early radiotherapy toxicity have more than twice the risk of developing late complications in prostate cancer treatment.

California Institute for Regenerative Medicine awards $5.8 million grant to UCLA researchers for developing hematopoietic stem cell gene therapy targeting Angelman syndrome.

The MIRAGE trial compared MRI-guided SBRT with CT-guided SBRT for prostate cancer, revealing reduced urinary and bowel toxicity.

• A phase II study evaluated Soylent, a liquid meal replacement, in head and neck cancer patients undergoing chemoradiation to prevent malnutrition and maximize quality of life. • The study demonstrated high patient adherence to Soylent, with 94% of patients successfully transitioning to exclusive meal replacement after experiencing a 5% body weight loss. • The gastrostomy tube (G-tube) placement rate was low at 5%, indicating effective nutritional support with Soylent during cancer treatment. • Patient-reported quality of life, initially reduced during treatment, rebounded to exceed baseline levels within six months, suggesting long-term benefits of Soylent.

A phase 2 trial comparing PSMA-PET/CT to bone scan/CT in metastatic castration-resistant prostate cancer (mCRPC) patients found similar detection rates between the two imaging modalities.